세계의 비결핵성 항산균 감염증 시장(2025년)

Nontuberculous Mycobacterial Infection Global Market Report 2025

US $ 4,490 ￦ 6,496,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,390,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,284,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비결핵성 항산균 감염증(NTM) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.7%로 195억 7,000만 달러로 성장할 것으로 예측됩니다. 예측 기간의 성장은 항균제 개발, 비결핵성 항산균 감염증에 대한 인식 증가, 유전자 연구 발전, 원격의료, 원격 모니터링에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 개인 맞춤형 치료, 규제 강화, 병용요법, 디지털 헬스 툴 등이 있습니다.

만성폐쇄성폐질환(COPD)의 유병률 증가는 향후 비결핵성 항산균 감염 시장의 성장을 촉진할 것으로 예상되며, COPD는 지속적 이고 점진적인 폐 기류 제한을 특징으로 하는 만성 호흡기 질환으로 비결핵성 항산균(NTM) 감염과 밀접한 관련이 있으며, 강제호기량(FEV1)이 더 현저하게 감소하고 악화율이 증가합니다. 가 더 현저하게 감소하고 악화율이 증가하며, COPD로 인한 면역력 저하와 폐 조직 손상으로 인해 NTM균에 의한 폐 감염에 더 취약해집니다. 예를 들어 2023년 3월 현재 스코틀랜드의 공중보건기관인 The Scottish Public Health Observatory(ScottPHO)는 2021-2022년에 COPD의 이환율이 상승하며, 남성의 이환율은 10만 명당 83.2명에서 97.6명으로, 여성의 이환율은 72.6명에서 97.3명으로 상승했다고 보고하고 있습니다. 결과적으로 만성폐쇄성폐질환(COPD)의 급증하는 유병률이 비결핵성 항산균 감염증 시장의 성장을 가속할 것으로 보입니다.

감염성 질환 유병률 증가는 향후 수년간 비결핵성 항산균(NTM) 감염성 질환 시장의 성장을 가속할 것으로 예상됩니다. 감염성 질환은 박테리아, 바이러스, 곰팡이, 기생충과 같은 유해한 미생물에 의해 발생하는 질병으로, 개인 간에 전염되어 다양한 증상과 건강 합병증을 유발하는 질병으로, NTM 감염을 포함한 감염성 질환의 발생률이 증가함에 따라 NTM 감염성 질환 시장은 성장할 것으로 예상됩니다. 이는 NTM 감염에 대한 인식이 높아지고, 진단 검사 빈도가 증가하고, 조기 발견이 가능해지며, NTM 치료제의 연구개발이 강화되고, 감염에 대한 의료계의 관심이 높아짐에 따라 NTM 병원체를 표적으로 하는 치료제에 대한 수요가 증가할 것으로 예상되기 때문입니다. 예를 들어 미국에 본부를 둔 정부 간 기구인 유엔아동기금(UNICEF)은 2024년 11월 폐렴이 연간 70만 명 이상의 어린이 사망을 유발하는 주요 감염 질환이며, 이는 하루에 약 2,000명이 사망하는 것과 같다고 보고했습니다. 따라서 감염성 질환의 유행이 증가하고 있는 것이 NTM 감염성 질환 시장의 성장을 가속하고 있습니다.

세계의 비결핵성 항산균 감염증 시장에 대해 조사했으며, 시장의 개요와 약제 클래스별, 투여 경로별, 유통 채널별, 유형별, 지역·국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 개요

제2장 비결핵성 항산균 감염증 시장의 특징

제3장 비결핵성 항산균 감염증 시장 동향과 전략

제4장 비결핵성 항산균 감염증 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 비결핵성 항산균 감염증의 확대 분석과 전략 분석 프레임워크

• 세계의 비결핵성 항산균 감염증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 용도 산업의 분석
• 세계의 비결핵성 항산균 감염증 시장의 성장률 분석
• 세계의 비결핵성 항산균 감염증 시장 규모 실적과 성장, 2019-2024년
• 세계의 비결핵성 항산균 감염증 시장 규모와 성장 예측, 2024-2029년, 2034년 예상
• 세계의 비결핵성 항산균 감염증 TAM(Total Addressable Market)

제6장 비결핵성 항산균 감염증 시장 세분화

• 세계의 비결핵성 항산균 감염증 시장, 약제 클래스별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• Macrolides
• Rifampin
• Aminoglycoside
• 기타
• 세계의 비결핵성 항산균 감염증 시장, 투여 경로별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 비경구
• 기타
• 세계의 비결핵성 항산균 감염증 시장, 유통 채널별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 비결핵성 항산균 감염증 시장, 마크로라이드의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• Azithromycin
• Clarithromycin
• 세계의 비결핵성 항산균 감염증 시장, 리판피신의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• Rifampin
• Rifabutin
• 세계의 비결핵성 항산균 감염증 시장, 아미노그리코시드의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
• Amikacin
• Streptomycin
• 세계의 비결핵성 항산균 감염증 시장, 기타 약제 클래스의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
• Ethambutol
• Clofazimine
• Linezolid

제7장 비결핵성 항산균 감염증 시장의 지역별·국가별 분석

• 세계의 비결핵성 항산균 감염증 시장, 지역별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
• 세계의 비결핵성 항산균 감염증 시장, 국가별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측

제8장 아시아태평양의 비결핵성 항산균 감염증 시장

제9장 중국의 비결핵성 항산균 감염증 시장

제10장 인도의 비결핵성 항산균 감염증 시장

제11장 일본의 비결핵성 항산균 감염증 시장

제12장 호주의 비결핵성 항산균 감염증 시장

제13장 인도네시아의 비결핵성 항산균 감염증 시장

제14장 한국의 비결핵성 항산균 감염증 시장

제15장 서유럽의 비결핵성 항산균 감염증 시장

제16장 영국의 비결핵성 항산균 감염증 시장

제17장 독일의 비결핵성 항산균 감염증 시장

제18장 프랑스의 비결핵성 항산균 감염증 시장

제19장 이탈리아의 비결핵성 항산균 감염증 시장

제20장 스페인의 비결핵성 항산균 감염증 시장

제21장 동유럽의 비결핵성 항산균 감염증 시장

제22장 러시아의 비결핵성 항산균 감염증 시장

제23장 북미의 비결핵성 항산균 감염증 시장

제24장 미국의 비결핵성 항산균 감염증 시장

제25장 캐나다의 비결핵성 항산균 감염증 시장

제26장 남미의 비결핵성 항산균 감염증 시장

제27장 브라질의 비결핵성 항산균 감염증 시장

제28장 중동의 비결핵성 항산균 감염증 시장

제29장 아프리카의 비결핵성 항산균 감염증 시장

제30장 비결핵성 항산균 감염증 시장의 경쟁 구도와 기업 개요

• 비결핵성 항산균 감염증 시장의 경쟁 구도
• 비결핵성 항산균 감염증 시장 기업 개요
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffman La Roche AG
  • Merck &Co. Inc.
  • AbbVie Inc.

제31장 비결핵성 항산균 감염증 시장 기타 대기업과 혁신적 기업

• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol Myers Squibb
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• C.H. Boehringer Sohn AG & Co. KG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.

제32장 세계의 비결핵성 항산균 감염증 시장의 경쟁 벤치마킹과 대시보드

제33장 비결핵성 항산균 감염증 시장에서의 주요 합병과 인수

제34장 비결핵성 항산균 감염증 시장의 최근 동향

제35장 비결핵성 항산균 감염증 시장의 잠재성이 높은 국가, 부문, 전략

• 2029년 비결핵성 항산균 감염증 시장 - 가장 새로운 기회를 제공하는 국가
• 2029년 비결핵성 항산균 감염증 시장 - 가장 새로운 기회를 제공하는 부문
• 2029년 비결핵성 항산균 감염증 시장 - 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

KSA

영문 목차

영문목차

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than Mycobacterium tuberculosis, which is responsible for tuberculosis (TB). NTM infections are primarily significant due to their impact on human health and their interaction with the immune system.

The primary classes of drugs used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a class of antibiotics commonly employed in the treatment of various bacterial infections. These drugs can be administered through different routes, including oral, parenteral (injectable), and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.25 billion in 2024 to $15.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is set to drive the growth of the nontuberculous mycobacterial infection market in the future. COPD, a chronic respiratory ailment characterized by persistent and often progressive lung airflow limitation, is closely linked to nontuberculous mycobacterial (NTM) infections, resulting in a more pronounced decline in forced expiratory volume in one second (FEV1) and an elevated exacerbation rate. The weakened immune system and lung tissue damage caused by COPD make it more susceptible to NTM bacterial lung infections. For example, as of March 2023, The Scottish Public Health Observatory (ScotPHO), a public health body in Scotland, reported a rise in COPD rates from 2021 to 2022, with male rates increasing from 83.2 to 97.6 per 100,000 individuals, and female rates rising from 72.6 to 97.3. Consequently, the burgeoning prevalence of chronic obstructive pulmonary disease (COPD) propels the nontuberculous mycobacterial infection market's growth.

The growing prevalence of infectious diseases is expected to drive the expansion of the nontuberculous mycobacterial (NTM) infection market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted between individuals, leading to a range of symptoms and health complications. As the incidence of infectious diseases, including those that can lead to NTM infections, rises, the market for NTM infections may experience growth. This is due to increased awareness of these infections, leading to more frequent diagnostic testing, earlier detection, enhanced research and development for NTM treatments, and a higher demand for therapies targeting NTM pathogens as healthcare attention on infectious diseases intensifies. For example, in November 2024, the United Nations International Children's Emergency Fund (UNICEF), a US-based intergovernmental organization, reported that pneumonia was the leading infectious disease responsible for the deaths of over 700,000 children annually, equating to around 2,000 deaths per day. Therefore, the rising prevalence of infectious diseases is driving the growth of the NTM infection market.

Leading companies in the nontuberculous mycobacterial (NTM) infection market are adopting new treatment approval strategies, such as Fast Track designation for drug approvals, to maintain their market position. The Fast Track designation, granted by the FDA, is a process that accelerates the development and review of drugs intended for serious conditions with unmet medical needs. For example, in July 2022, the U.S.-based Food and Drug Administration (FDA) granted Fast Track Designation to NUZYRA for the treatment of NTM lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic developed to fight serious bacterial infections, including those caused by resistant strains. This designation helps speed up the development and review process for NUZYRA, addressing critical unmet medical needs.

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, entered into a partnership with TB Alliance with the goal of developing telacebec, a drug for the treatment of tuberculosis and other nontuberculous mycobacterial (NTM) infections. The partnership grants TB Alliance the exclusive global license for Telacebec. This signifies that TB Alliance will have the authority to continue its work on the medicine and market it on an international scale. TB Alliance, a South Africa-based non-profit organization, is dedicated to developing and delivering cost-effective TB medications.

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nontuberculous Mycobacterial Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nontuberculous mycobacterial infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nontuberculous mycobacterial infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nontuberculous mycobacterial infection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
• 2) By Route Of Administration: Oral; Parenteral; Other Routes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Macrolides: Azithromycin; Clarithromycin
• 2) By Rifampin: Rifampin; Rifabutin
• 3) By Aminoglycoside: Amikacin; Streptomycin
• 4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffman La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nontuberculous Mycobacterial Infection Market Characteristics

3. Nontuberculous Mycobacterial Infection Market Trends And Strategies

4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nontuberculous Mycobacterial Infection Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nontuberculous Mycobacterial Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nontuberculous Mycobacterial Infection Market Growth Rate Analysis
• 5.4. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nontuberculous Mycobacterial Infection Total Addressable Market (TAM)

6. Nontuberculous Mycobacterial Infection Market Segmentation

• 6.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrolides
• Rifampin
• Aminoglycoside
• Other Drug Classes
• 6.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azithromycin
• Clarithromycin
• 6.5. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rifampin
• Rifabutin
• 6.6. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amikacin
• Streptomycin
• 6.7. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ethambutol
• Clofazimine
• Linezolid

7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis

• 7.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nontuberculous Mycobacterial Infection Market

• 8.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nontuberculous Mycobacterial Infection Market

• 9.1. China Nontuberculous Mycobacterial Infection Market Overview
• 9.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nontuberculous Mycobacterial Infection Market

• 10.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nontuberculous Mycobacterial Infection Market

• 11.1. Japan Nontuberculous Mycobacterial Infection Market Overview
• 11.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nontuberculous Mycobacterial Infection Market

• 12.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nontuberculous Mycobacterial Infection Market

• 13.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nontuberculous Mycobacterial Infection Market

• 14.1. South Korea Nontuberculous Mycobacterial Infection Market Overview
• 14.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nontuberculous Mycobacterial Infection Market

• 15.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview
• 15.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nontuberculous Mycobacterial Infection Market

• 16.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nontuberculous Mycobacterial Infection Market

• 17.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nontuberculous Mycobacterial Infection Market

• 18.1. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nontuberculous Mycobacterial Infection Market

• 19.1. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nontuberculous Mycobacterial Infection Market

• 20.1. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nontuberculous Mycobacterial Infection Market

• 21.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview
• 21.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nontuberculous Mycobacterial Infection Market

• 22.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nontuberculous Mycobacterial Infection Market

• 23.1. North America Nontuberculous Mycobacterial Infection Market Overview
• 23.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nontuberculous Mycobacterial Infection Market

• 24.1. USA Nontuberculous Mycobacterial Infection Market Overview
• 24.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nontuberculous Mycobacterial Infection Market

• 25.1. Canada Nontuberculous Mycobacterial Infection Market Overview
• 25.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nontuberculous Mycobacterial Infection Market

• 26.1. South America Nontuberculous Mycobacterial Infection Market Overview
• 26.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nontuberculous Mycobacterial Infection Market

• 27.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nontuberculous Mycobacterial Infection Market

• 28.1. Middle East Nontuberculous Mycobacterial Infection Market Overview
• 28.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nontuberculous Mycobacterial Infection Market

• 29.1. Africa Nontuberculous Mycobacterial Infection Market Overview
• 29.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles

• 30.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape
• 30.2. Nontuberculous Mycobacterial Infection Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffman La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol Myers Squibb
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GlaxoSmithKline plc
• 31.8. Takeda Pharmaceutical Company
• 31.9. Eli Lilly and Company
• 31.10. C.H. Boehringer Sohn AG & Co. KG
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Mylan N.V.
• 31.13. Astellas Pharma Inc.
• 31.14. Vertex Pharmaceuticals Inc.
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market

34. Recent Developments In The Nontuberculous Mycobacterial Infection Market

35. Nontuberculous Mycobacterial Infection Market High Potential Countries, Segments and Strategies

• 35.1 Nontuberculous Mycobacterial Infection Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nontuberculous Mycobacterial Infection Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nontuberculous Mycobacterial Infection Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료